A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Combination Product: LVGN6051 Monoclonal Antibody Injection+toripalimab Injection+paclitaxel Injection Sponsors: Lyvgen Biopharma Holdings Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials